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Abstract
Introduction: The Sysmex XN-series haematology analyser has newly adopted a fluorescent channel to measure immature  platelet  fracti-
on (IPF). To promote the clinical utility of this promising parameter, establishing a reliable reference interval is mandatory. According to previous 
studies, IPF values may be affected by the employed analyser and the ethnic background of the individual, but no differences seem to be found 
between individuals’ genders. Therefore, this study aimed to define the reference interval for IPF in a Spanish population following Clinical and La-
boratory Standard Institute (CLSI) guidelines.
Materials and methods: A total of 153 healthy Caucasian adults from Spain met the inclusion criteria. IPF measurement was performed by means 
of a Sysmex XN-2000 haematology analyser. A non-parametric percentile method was used to calculate the reference intervals in accordance with 
CLSI guidelines.
Results: The obtained reference interval for IPF on the Sysmex XN-2000 was 1.6–9.6% (90% confidence intervals (CIs) were 1.5–1.8 and 9.3–11.5, 
respectively). No significant gender difference in IPF reference intervals was observed (P = 0.101). 
Conclusions: This study provides, for the first time, a reference interval for IPF using a Sysmex XN-2000 in a Spanish population, ranging from 1.6 
to 9.6%. These data are needed to evaluate platelet production in several conditions such as thrombocytopenia, inflammatory states and cardiovas-
cular diseases, as well as for future research. 
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In the last decades, automated haematology ana-
lysers have undergone important technological 
upgrades, such as the introduction of new meth-
ods and channels, the optimization of reagents 
and an improvement in analysis algorithms. This 
has resulted in an optimization of the analytical 
characteristics and in an increase in the obtained 
information. However, this additional information 
and the potential clinical uses of the new parame-
ters have not been widely studied. This is the case 
with immature platelet fraction (IPF), which is a 
new parameter that measures young or immature 
platelets in peripheral blood. This parameter is 
usually expressed as a proportional value of the 
total platelet count (%-IPF), as well as absolute im-
mature platelet (A-IPF), which is a derived value 
from the total platelet count and %-IPF.
Immature platelets are the newly released plate-
lets from the bone marrow by megakaryocytes. 
They have a short lifespan (< 24 hours) (1). The IPF 
is a helpful and non-invasive biomarker for the di-
agnosis of thrombocytopenia. It makes a distinc-
tion between central failures and peripheral plate-
let destruction because it is an indicator of mega-
kariopoetic activity (2,3). Bone marrow activity is 
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low in patients with central thrombocytopenia, so 
the IPF would be low. In contrast, in conditions 
where there is peripheral platelet destruction the 
bone marrow activity is accelerated and the IPF 
would be high (2).
Immature platelet fraction can also be an early 
predictor of bone marrow recovery after chemo-
therapy and stem cell transplantation (4,5). Gener-
ally, IPF values increase several days prior to a rise 
in the platelet count avoiding unnecessary platelet 
transfusions (6). 
In recent years, several potential uses of IPF have 
been reported in the literature related to cardio-
vascular outcomes and inflammatory conditions 
(7-11). Many studies suggest that a higher propor-
tion of IPF is associated with worse clinical out-
comes in patients with cardiovascular diseases 
and in acute coronary syndromes (7,9). Immature 
platelets are metabolically and enzymatically 
more active than mature ones, having a greater 
prothrombotic activity. In consequence, some au-
thors have hypothesized that IPF values may guide 
antiplatelet therapy as a marker of platelet turno-
ver. Due to the major prothrombotic activity, a 
higher proportion of IPF could be associated with 
an attenuated response to antiplatelet drugs (12).
Recent studies suggest that IPF can provide clini-
cal information about inflammatory conditions (8). 
In patients with sepsis, the activity of the bone 
marrow may also result in the release of an in-
creased concentration of myeloid precursors and 
earlier platelets in peripheral blood. The mecha-
nism inducing the increase in the production of 
IPF in septic patients could be related to the in-
crease in cytokine production which occurs due to 
the inflammatory state (13).
At the beginning, IPF was measured by means of 
staining for RNA assessed by flow cytometry. How-
ever, this method had several limitations, such as 
being very time-consuming, having a high cost 
and a lack of standardization. Nowadays, automat-
ed IPF measurement is integrated into routine 
haematology analysers. For example, the newly 
developed Sysmex XN-series haematology analys-
er adopts a new platelet fluorescent channel (PLT-
F) to measure IPF. 
Despite the above-mentioned clinical benefits, 
the provision of reliable reference intervals for IPF 
is necessary to evaluate its usefulness and avoid 
misdiagnoses. The International Federation of 
Clinical Chemistry (IFCC) and Clinical and Labora-
tory Standard Institute (CLSI) recommend that all 
clinical laboratories should develop their own bio-
logical reference intervals (14). However, few labo-
ratories currently follow this recommendation be-
cause of its difficulty, great time consumption and 
high costs. 
The reference interval for IPF in a Spanish popula-
tion employing the Sysmex XN-series have not yet 
been studied. According to previous studies, IPF 
values are highly dependent on the analyser used 
and also on ethnic background, but usually no dif-
ferences between genders are found (15,16). Given 
these facts, our hypothesis is that reference inter-
vals performed using the XE-series may not be ap-
propriate for the XN-series. Moreover, the previ-
ously reported reference intervals established us-
ing the XN-series were developed in an Asian pop-
ulation, hence they too may not be valid for the 
Spanish population. 
For all these reasons, the aim of the present work 
was to define 95% reference limits for IPF using 
the Sysmex XN-2000 in an adult Spanish popula-
tion following CLSI guidelines.
Materials and methods
Subjects
The study was performed at Bellvitge University 
Hospital (Barcelona, Spain) which is a 700-bed 
teaching hospital specialized in adult patient care. 
The clinical laboratory is accredited according to 
the International Standard ISO 15189. 
A total of 164 Caucasian volunteers from Spain 
were enrolled in this study from December 2015 to 
September 2016. Inclusion criteria for individuals 
were the following:  ≥ 16 years old and apparently 
healthy adults. Exclusion criteria were the follow-
ing: any acute or chronic disease, pregnancy, do-
nating blood or receiving a blood transfusion in 
the past year, history of alcoholism, smoking > 20 
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cigarettes per day and taking any drug known to 
affect the platelet number or activity (e.g. salicy-
lates). Moreover, to exclude unhealthy individuals, 
blood, serum and plasma were obtained from 
each volunteer to assess the complete blood 
count (CBC), biomarkers for liver and renal func-
tion, iron status and coagulation. Subjects were 
excluded if any laboratory results were outside the 
reference intervals used in our clinical laboratory. 
This study was approved by the Clinical Research 
Ethics Committee of Bellvitge University Hospital. 
A completed questionnaire and written informed 
consent were obtained from each individual.
Methods
Blood samples were collected in 4 mL tubes con-
taining ethylenediaminetetraacetic acid (K3EDTA) 
(Vaccuette®, Greiner Bio One®, Kremsmünster, Aus-
tria) and stored at room temperature before IPF 
measurement. All samples were analysed within 
2–4 hours of collection. Complete blood count 
and IPF were measured using a Sysmex XN-2000 
(Sysmex, Kobe, Japan) according to the manufac-
turer’s recommendation. The Sysmex XN-series 
adopts fluorescent flow cytometry with semicon-
ductor diode laser to measure IPF. Briefly, oxazine 
fluorescent dyes penetrate the platelets and stain 
the RNA. The stained platelets are passed through 
a semiconductor diode laser beam and the result-
ing forward scatter light (volume) and fluores-
cence intensity (mRNA content) are measured. The 
mature and immature platelets are identified on 
the basis of their fluorescence intensity. The IPF is 
expressed as a proportional value (%-IPF) of the 
total platelet count to indicate the rate of platelet 
production. 
Throughout the study period, three levels of qual-
ity control material (QC-XN-CHECK levels 1, 2 and 
3; Streck Laboratories Inc., Omaha, USA) were per-
formed for all routine parameters, fluorescent 
platelets count and IPF, to control the performance 
of the overall procedure and the instrument under 
use.
Within- and between-day imprecision and relative 
bias were estimated for IPF using the lower QC 
material. The IPF conventional value was assigned 
by the manufacturer. The desirable limits for with-
in- and between-day analytical variations (CVA) 
and relative bias were defined by Bouro et al. (17). 
The within- and between-day imprecision ob-
tained were 1.6 and 2.6%, respectively (desirable 
limit: 3.9%) and - 2.6% for relative bias (desirable 
limit: 11.9%). The metrological characteristics for 
IPF measurement did not exceed the desirable 
limits reported (17).
In addition, in order to exclude potentially un-
healthy individuals, serum was collected in serum 
gel tubes and plasma in sodium citrate solution 
tubes (Vacuette®, Greiner Bio-One GmbH®, Krems-
münster, Austria) to measure all biochemical pa-
rameters on a Cobas 8000 (Roche Diagnostics®, Ba-
sel, Switzerland) and coagulation parameters on 
an ACL-TOP 500 CTS (Instrumentation Laboratory 
Company®, Bedford, USA), respectively.
Statistical analysis 
All calculations to determine reference intervals 
were based on the CLSI guidelines (document 
EP28-A3c) (14). 
Outliers were detected and removed using the ad-
justed Tukey’s test. The distribution plot was per-
formed to visually inspect the data. The Kolmogo-
rov–Smirnov test was used to assess the normality 
of distribution of the data.
According to the normality of the data, appropriate 
measures and statistical tests were used.  Normally 
distributed data were expressed as mean ± stand-
ard deviation (SD). The non-normally distributed 
data were expressed as median and interquartile 
range (IQR). Significance of between-group differ-
ences was tested by the parametric independent t-
test and non-parametric Mann-Whitney test. 
The IPF median values in males and females were 
compared using the Mann–Whitney U-test. When 
the results did not warrant partitioning, data were 
combined to calculate the reference interval.
The reference interval was calculated using a non-
parametric method for lower and upper reference 
limits as 2.5% and 97.5% of the reference distribu-
tion. The 90% confidence intervals (CI) were calcu-
lated for lower and upper reference limits.
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The values P < 0.05 were considered statistically 
significant. Statistical analysis was performed us-
ing STATA® version 14 (StataCorp LP, Texas, USA). 
Results
Blood samples were obtained from all eligible par-
ticipants (N = 164). Three subjects were excluded 
due to abnormal total platelet count (in-house ref-
erence values: 149–303 and 153–368 x109/L for 
males and females, respectively), and one subject 
due to low haemoglobin concentration (WHO ref-
erence values: > 130 and > 120 g/L for male and 
females, respectively). In total, four participants 
did not fulfill all the inclusion criteria and were re-
moved from further analysis. In addition, seven ex-
treme values were detected and discarded as out-
liers. In summary, 153 subjects, comprising 73 
males and 80 females, were enrolled for calculat-
ing the reference intervals for IPF on a Sysmex XN-
2000. 
The median age (min, max) of the total group was 
37 (19–76) years. The median age of males and fe-
males was 31 (19–76) and 41 (20–68) years, respec-
tively (P = 0.074). 
The distribution of the complete reference data 
for total platelet count, %-IPF and A-IPF, are pre-
sented in a scatter plot (Figure 1). The distribution 
for platelet count was Gaussian (P = 0.435) and for 
%-IPF and A-IPF was non-Gaussian (P < 0.001 and 
P = 0.002, respectively), showing left-skewed his-
tograms.
Data for total platelet count, %-IPF and A-IPF from 
healthy individuals are presented in Table 1. No 
statistical differences were observed between 
genders in any of these three parameters. 
Finally, the reference interval and 90% correspond-
ing confidence intervals (90%CI) for IPF in total in-
dividuals were 1.6 (90%CI: 1.5–1.8) – 9.6 (90%CI: 
9.3–11.5)%.
Discussion
Nowadays, automated haematology analysers 
have been improved to enable the measurement 
of immature platelets. In the present research, we 
Figure 1. (A) Distribution of platelet count. (B) Distribution of 
immature platelet fraction (IPF). (C) Distribution of absolute im-
mature platelet count (A-IPF) in reference individuals (N = 153).

























































show, for the first time, the reference interval for 
IPF in a Spanish cohort using the Sysmex XN-2000. 
The reference values estimated were 1.6–9.6%, in-
dependent of gender.
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To promote the clinical use of IPF, establishing reli-
able reference interval should be mandatory. To 
the best of our knowledge, no data are available 
for IPF adult reference intervals in a Spanish or 
southern European population in Sysmex XN-se-
ries analysers. Therefore, we aimed to define 95% 
reference limits for IPF and, whenever relevant, es-
tablish separate reference intervals according to 
gender. On the basis of our results and in accord-
ance with previously reported data, we did not 
confirm statistically significant differences of refer-
ence intervals for male versus female for IPF 
(2,15,18,19). Thus, we assume that a gender-specific 
reference interval would be unnecessary. 
The upper reference limit established in this study 
is somewhat higher than in previously published 
papers, ranging from 3.2 up to 7.1% (2,15,20). One 
can remark that all of these studies were per-
formed with a Sysmex XE-series analyser. In com-
parison with the Sysmex XE, the Sysmex XN seems 
to be higher in %IPF. This fact was also described 
by Ko et al. (16). According to Van der Linden et al. 
and Ko et al., the higher reference intervals of IPF 
obtained with the XN compared with the XE series 
may reflect the fact that both analysers have dif-
ferent metrological characteristics and that IPF 
measured on the XN series has a better precision 
and accuracy than when measured on the XE se-
ries (5,16). With the introduction of the XN series, 
the principles, channel, reagent and algorithm to 
detect IPF have been changed. Given these differ-
ences, IPF results will be more specific and this 
suggests the necessity of new reference intervals 
for IPF. 
Nevertheless, in contrast with our hypothesis, the 
reference intervals reported previously in a Korean 
population using the Sysmex XN are similar to the 
current study, between 1 and 9% (16). These re-
sults suggest that IPF values seem to be more af-
fected by the analyser used than the ethnic back-
ground of the individuals.  
This study was, however, limited by the small num-
ber of enrolled reference individuals. Neverthe-
less, it was enough to establish the reference inter-
vals following the CLSI guidelines. Also, it has to be 
taken into account that age differences have not 
been assessed in the establishment of reference 
intervals. Despite this, previous studies indicate 
that no differences were found in IPF results when 
stratifying by age (18,19). Finally, this study did not 
establish the reference intervals for A-IPF. Howev-
er, the clinical utilities of immature platelets, ex-
pressed as a proportional value (%-IPF), are more 
widely reported in the literature than A-IPF.
In conclusion and to the best of our knowledge, 
we have generated the first report on reference in-
tervals of IPF in a Spanish population using the 
Sysmex XN-2000 haematology analyser. The es-
tablished reference interval for IPF was 1.6–9.6%, 
independent of gender. These results may be of 
benefit to the laboratories using the Sysmex XN-
series analyser, making an accurate interpretation 
of patients’ results much easier. 
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(N = 80) P value
Platelet count (x109/L) 235 ± 47 230 ± 43 240 ± 50 0.158*
IPF (%) 4.3 (2.9-6.2) 4.1 (2.6-5.9) 4.7 (3.3-6.4) 0.101†
A-IPF (x109/L) 10.23 (6.81-14.16) 9.46 (6.20-13.24) 11.02 (7.59-15.05) 0.071†
Data are expressed as a mean ± standard deviation for platelet count, and as a median (IQR) for IPF and A-IPF. *Differences 
between men and women were tested using the t-student's test. †Differences between men and women were tested using the 
Mann-Whitney U test. IPF - immature platelet fraction. A-IPF - absolute immature platelet count.
Table 1. Platelet count, immature platelet fraction and absolute number from healthy individuals.
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